APA (7th ed.) Citation

T, K., S, K., T, Y., K, M., W, F., K, K., . . . M, A. (2025). Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy. Scientific reports, 15(1), 27163. https://doi.org/10.1038/s41598-025-08767-9

Chicago Style (17th ed.) Citation

T, Kawada, et al. "Eosinophils as a Predictive Marker of Treatment-related Adverse Events in MRCC Patients Treated with First-line Immune-checkpoint Inhibitor Combination Therapy." Scientific Reports 15, no. 1 (2025): 27163. https://doi.org/10.1038/s41598-025-08767-9.

MLA (9th ed.) Citation

T, Kawada, et al. "Eosinophils as a Predictive Marker of Treatment-related Adverse Events in MRCC Patients Treated with First-line Immune-checkpoint Inhibitor Combination Therapy." Scientific Reports, vol. 15, no. 1, 2025, p. 27163, https://doi.org/10.1038/s41598-025-08767-9.